SCHEMBL4808835

SCHEMBL4808835

CCN(CC)CC.NC(Cc1cc(Br)c(OCc2cccc(Cl)c2)c(Br)c1)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRA P10827 7/20 0.56
THRB P10828 7/20 0.56
SLC1A5 Q15758 1/20 0.50
ESR1 P03372 1/20 0.44
NR3C1 P04150 1/20 0.44
PGR P06401 1/20 0.44
NR3C2 P08235 1/20 0.44
AR P10275 1/20 0.44
MAOB P27338 3/20 0.44
MAOA P21397 2/20 0.44
MEN1 O00255 1/20 0.44
LMNA P02545 1/20 0.44
CYP1A2 P05177 1/20 0.44
HSP90AA1 P07900 1/20 0.44
CYP3A4 P08684 1/20 0.44
MAPT P10636 1/20 0.44
XBP1 P17861 1/20 0.44
CYP2C19 P33261 1/20 0.44
KMT2A Q03164 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4816034 0.89 THRB (0.47) THRATHRBNR3C1PGRMEN1
SCHEMBL4810919 0.89 THRA (0.50) THRATHRBESR1NR3C1PGR
SCHEMBL4818644 0.86 THRA (0.48) THRATHRBSLC1A5ESR1NR3C1
SCHEMBL4808246 0.84 THRA (0.46) THRATHRBSLC1A5ESR1NR3C1
SCHEMBL4815513 0.83 SLC1A5 (0.49) THRATHRBSLC1A5MAOBMAOA
SCHEMBL4809557 0.83 THRA (0.45) THRATHRBMAOBMEN1LMNA
SCHEMBL4812326 0.82 THRA (0.64) THRATHRBESR1NR3C1PGR
SCHEMBL4899376 0.82 THRA (0.64) THRATHRBESR1NR3C1PGR
SCHEMBL4809817 0.82 THRB (0.46) THRATHRBNR3C1PGRMAOB
SCHEMBL4812514 0.80 SLC1A5 (0.47) THRATHRBSLC1A5MAOBPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7319096-B2 Thyroid hormone receptor antagonists for cardiac and metabolic disorders II KARO BIO AB (SE) 2008-01-15 US claimed
US-20040220147-A1 Thyroid hormone receptor antagonists for cardiac and metabolic disorders ll KARO BIO AB (SE) 2004-11-04 US claimed
EP-1387825-A1 THYROID HORMONE RECEPTOR ANTAGONISTS FOR CARDIAC & METABOLIC DISORDERS II KARO BIO AB (SE) 2004-02-11 EP claimed
WO-2002092550-A1 THYROID HORMONE RECEPTOR ANTAGONISTS FOR CARDIAC AND METABOLIC DISORDERS II KARO BIO AB (SE) 2002-11-21 WO claimed
US-7319096-B2 Thyroid hormone receptor antagonists for cardiac and metabolic disorders II KARO BIO AB (SE) 2008-01-15 US disclosed
US-20040220147-A1 Thyroid hormone receptor antagonists for cardiac and metabolic disorders ll KARO BIO AB (SE) 2004-11-04 US disclosed
EP-1387825-A1 THYROID HORMONE RECEPTOR ANTAGONISTS FOR CARDIAC & METABOLIC DISORDERS II KARO BIO AB (SE) 2004-02-11 EP disclosed
WO-2002092550-A1 THYROID HORMONE RECEPTOR ANTAGONISTS FOR CARDIAC AND METABOLIC DISORDERS II KARO BIO AB (SE) 2002-11-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220147-A1 Thyroid hormone receptor antagonists for cardiac and metabolic disorders ll TSHR, TRHR, THRA THRA 3/4885THRB 4/4885SLC1A5 1125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.